Anne Pham-Ledard1, Marie Beylot-Barry2, Coralie Barbe3, Marion Leduc4, Tony Petrella5, Béatrice Vergier6, Fabian Martinez7, David Cappellen8, Jean-Philippe Merlio9, Florent Grange10. 1. Equipe d'accueil 2406, Histology and Molecular Pathology of Tumors, Universitaire Bordeaux, Bordeaux, France2Department of Dermatology, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France. 2. Equipe d'accueil 2406, Histology and Molecular Pathology of Tumors, Universitaire Bordeaux, Bordeaux, France2Department of Dermatology, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France3French Study Group for Cutaneous Lymphomas, France. 3. Unité d'Aide Méthodologique, Hôpital Robert Debré, Reims, France. 4. Department of Clinical Research, Hôpital Maison Blanche, Centre Hospitalier Universitaire Reims, Reims, France. 5. French Study Group for Cutaneous Lymphomas, France6Department of Pathology, Centre Hospitalier Universitaire Dijon, Dijon, France. 6. Equipe d'accueil 2406, Histology and Molecular Pathology of Tumors, Universitaire Bordeaux, Bordeaux, France3French Study Group for Cutaneous Lymphomas, France7Department of Pathology, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France. 7. Tumor Bank and Tumor Biology Laboratory, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France. 8. Equipe d'accueil 2406, Histology and Molecular Pathology of Tumors, Universitaire Bordeaux, Bordeaux, France8Tumor Bank and Tumor Biology Laboratory, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France. 9. Equipe d'accueil 2406, Histology and Molecular Pathology of Tumors, Universitaire Bordeaux, Bordeaux, France3French Study Group for Cutaneous Lymphomas, France8Tumor Bank and Tumor Biology Laboratory, Centre Hospitalier Universitaire Bordeaux, Bordeaux, F. 10. French Study Group for Cutaneous Lymphomas, France9Department of Dermatology, Hôpital Robert Debré, Centre Hospitalier Universitaire Reims, Reims, France.
Abstract
IMPORTANCE: The activating mutation of MYD88 L265P is a frequent feature of primary cutaneous diffuse large B-cell lymphoma, leg-type (PCLBCL-LT), reported in up to 69% of the cases. Whether patients with MYD88 mutation display specific clinical and evolutive features has not been evaluated. OBJECTIVE: To identify the clinical characteristics associated with MYD88 mutation, confirm its high prevalence, and evaluate its effect on prognosis in patients with PCLBCL-LT. DESIGN, SETTING, AND PARTICIPANTS: A retrospective multicenter study was conducted using the medical records of patients from dermatology departments belonging to the French Study Group for Cutaneous Lymphomas. Sixty-one patients with a diagnosis of PCLBCL-LT made between 1988 and 2010 who were available for molecular study were included. Of these, 58 patients displaying interpretable results constituted the study group. Median follow-up was 33 months, and 39 patients (67%) were monitored until death. MAIN OUTCOMES AND MEASURES: Clinical features (age, sex, number of skin lesions, tumor stage, and location as leg vs elsewhere), MYD88 mutation (allele-specific TaqMan polymerase chain reaction assay), treatment regimen, and outcome were recorded. Baseline characteristics and outcome were compared according to the status of MYD88. RESULTS: The median age of the patients was 79 years, and 59% were female. Skin lesions were located on the leg in 76% of the cases. Thirty-four of 58 patients (59%) harbored the MYD88 L265P mutation. Patients had similar clinical characteristics at presentation regardless of their MYD88 status, except that those harboring the MYD88 mutation were older (P = .006) and had more frequent involvement of the leg (P = .008). Patients harboring the MYD88 mutation had 3- and 5-year-specific survival rates of 65.7% and 60.2% vs 85.4% and 71.7% in patients with the wild-type allele. The MYD88 mutation was significantly associated with shorter disease-specific survival in univariate (P = .03) and multivariate (odds ratio, 3.01; 95% CI, 1.03-8.78; P = .04) analysis. There was no significant difference between the groups in their treatment regimens. Considering overall survival, in univariate (P = .002) and multivariate (odds ratio, 2.94; 95% CI, 1.18-7.30; P = .02) analysis, MYD88 L265P mutation was an independent adverse prognostic factor. CONCLUSIONS AND RELEVANCE: This study confirms the high prevalence of MYD88 L265P mutation in PCLBCL-LT and shows its association with shorter survival. The clinical effect of MYD88 mutation activating the nuclear factor-κB pathway supports the use of targeted therapies at the time of relapse after conventional therapies.
IMPORTANCE: The activating mutation of MYD88L265P is a frequent feature of primary cutaneous diffuse large B-cell lymphoma, leg-type (PCLBCL-LT), reported in up to 69% of the cases. Whether patients with MYD88 mutation display specific clinical and evolutive features has not been evaluated. OBJECTIVE: To identify the clinical characteristics associated with MYD88 mutation, confirm its high prevalence, and evaluate its effect on prognosis in patients with PCLBCL-LT. DESIGN, SETTING, AND PARTICIPANTS: A retrospective multicenter study was conducted using the medical records of patients from dermatology departments belonging to the French Study Group for Cutaneous Lymphomas. Sixty-one patients with a diagnosis of PCLBCL-LT made between 1988 and 2010 who were available for molecular study were included. Of these, 58 patients displaying interpretable results constituted the study group. Median follow-up was 33 months, and 39 patients (67%) were monitored until death. MAIN OUTCOMES AND MEASURES: Clinical features (age, sex, number of skin lesions, tumor stage, and location as leg vs elsewhere), MYD88 mutation (allele-specific TaqMan polymerase chain reaction assay), treatment regimen, and outcome were recorded. Baseline characteristics and outcome were compared according to the status of MYD88. RESULTS: The median age of the patients was 79 years, and 59% were female. Skin lesions were located on the leg in 76% of the cases. Thirty-four of 58 patients (59%) harbored the MYD88L265P mutation. Patients had similar clinical characteristics at presentation regardless of their MYD88 status, except that those harboring the MYD88 mutation were older (P = .006) and had more frequent involvement of the leg (P = .008). Patients harboring the MYD88 mutation had 3- and 5-year-specific survival rates of 65.7% and 60.2% vs 85.4% and 71.7% in patients with the wild-type allele. The MYD88 mutation was significantly associated with shorter disease-specific survival in univariate (P = .03) and multivariate (odds ratio, 3.01; 95% CI, 1.03-8.78; P = .04) analysis. There was no significant difference between the groups in their treatment regimens. Considering overall survival, in univariate (P = .002) and multivariate (odds ratio, 2.94; 95% CI, 1.18-7.30; P = .02) analysis, MYD88L265P mutation was an independent adverse prognostic factor. CONCLUSIONS AND RELEVANCE: This study confirms the high prevalence of MYD88L265P mutation in PCLBCL-LT and shows its association with shorter survival. The clinical effect of MYD88 mutation activating the nuclear factor-κB pathway supports the use of targeted therapies at the time of relapse after conventional therapies.
Authors: Xiaolong Alan Zhou; Abner Louissaint; Alexander Wenzel; Jingyi Yang; Maria Estela Martinez-Escala; Andrea P Moy; Elizabeth A Morgan; Christian N Paxton; Bo Hong; Erica F Andersen; Joan Guitart; Amir Behdad; Lorenzo Cerroni; David M Weinstock; Jaehyuk Choi Journal: J Invest Dermatol Date: 2018-05-30 Impact factor: 8.551
Authors: Rein Willemze; Lorenzo Cerroni; Werner Kempf; Emilio Berti; Fabio Facchetti; Steven H Swerdlow; Elaine S Jaffe Journal: Blood Date: 2019-01-11 Impact factor: 22.113
Authors: Steven H Swerdlow; Isinsu Kuzu; Ahmet Dogan; Stephan Dirnhofer; John K C Chan; Birgitta Sander; German Ott; Luc Xerri; Leticia Quintanilla-Martinez; Elias Campo Journal: Virchows Arch Date: 2015-10-10 Impact factor: 4.064
Authors: Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Atanas Kamburov; Robert A Redd; Mike S Lawrence; Margaretha G M Roemer; Amy J Li; Marita Ziepert; Annette M Staiger; Jeremiah A Wala; Matthew D Ducar; Ignaty Leshchiner; Ester Rheinbay; Amaro Taylor-Weiner; Caroline A Coughlin; Julian M Hess; Chandra S Pedamallu; Dimitri Livitz; Daniel Rosebrock; Mara Rosenberg; Adam A Tracy; Heike Horn; Paul van Hummelen; Andrew L Feldman; Brian K Link; Anne J Novak; James R Cerhan; Thomas M Habermann; Reiner Siebert; Andreas Rosenwald; Aaron R Thorner; Matthew L Meyerson; Todd R Golub; Rameen Beroukhim; Gerald G Wulf; German Ott; Scott J Rodig; Stefano Monti; Donna S Neuberg; Markus Loeffler; Michael Pfreundschuh; Lorenz Trümper; Gad Getz; Margaret A Shipp Journal: Nat Med Date: 2018-04-30 Impact factor: 53.440